Real-world outcomes after anti-IL-5/anti-IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review.

ABSTRACT:

Background

Anti-IL-5/anti-IL-5 receptor alpha (anti-IL-5/anti-IL-5Rα) treatments have potential to improve outcomes in hypereosinophilic syndrome (HES), as demonstrated in clinical trials.

Objective

We sought to understand the real-world outcomes of anti-IL-5/anti-IL-5Rα treatments in patients with HES.

Methods

This systematic literature review searched English-language articles (November 4, 2015, to October 31, 2023) and conference abstracts (January 1, 2021, to October 31, 2023) from MEDLINE/Embase and select conferences for publications containing outcomes for patients with HES receiving anti-IL-5 (mepolizumab [approved], reslizumab) or anti-IL-5Rα (benralizumab) treatment in the real world. Meta-analyses and clinical trials were excluded. Outcomes included treatme

SUBMITTER: Jain P 

PROVIDER: S-EPMC12755987 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature